News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VGX International Signs a Master Product Sale Agreement with BioCancell Therapeutics of Israel to Supply Plasmid for Its Multiple Clinical Programs


10/27/2008 11:17:26 AM

THE WOODLANDS, Texas--(BUSINESS WIRE)--VGXI, Inc. today announced the execution of a Master Product Sale Agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics. BioCancell is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. Products under the Agreement will be manufactured at the VGXI, Inc production facility in The Woodlands, TX.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES